Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization


Por: Sanchez-Heras A, Castillejo A, Garcia-Diaz J, Robledo M, Teule A, Sanchez R, Zuniga A, Lastra E, Duran M, Llort G, Yague C, Cajal T, San Martin C, Lopez-Fernandez A, Balmana J, Robles L, Mesa-Latorre J, Chirivella I, Fonfria M, Ibanez R, Castillejo M, Escandell I, Gomez L, Berbel P, Soto J

Publicada: 1 nov 2020
Resumen:
Simple Summary Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancer (RCC), with no data on its prevalence worldwide. No genotype-phenotype associations have been described. The aim of our study was to describe the genotypic and phenotypic features of the largest series of patients with HLRCC from Spain reported to date. Of 27 FH germline pathogenic variants, 12 were not previously reported in databases. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function variants. The frequency of RCCs (10.9%) was lower than those reported in the previously published series. Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancers (RCCs). We aimed to describe the genetics, clinical features and potential genotype-phenotype associations in the largest cohort of fumarate hydratase enzyme mutation carriers known from Spain using a multicentre, retrospective study of individuals with a genetic or clinical diagnosis of HLRCC. We collected clinical information from medical records, analysed genetic variants and looked for genotype-phenotype associations. Analyses were performed using R 3.6.0. software. We included 197 individuals: 74 index cases and 123 relatives. CLMs were diagnosed in 65% of patients, ULMs in 90% of women, RCys in 37% and RCC in 10.9%. Twenty-seven different pathogenic variants were detected, 12 (44%) of them not reported previously. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function variants (p = 0.0380, p = 0.0015 and p = 0.024, respectively). This is the first report of patients with HLRCC from Spain. The frequency of RCCs was lower than those reported in the previously published series. Individuals with missense pathogenic variants had higher frequencies of CLMs, ULMs and RCys.

Filiaciones:
Sanchez-Heras A:
 Hosp Gen Univ Elche, Med Oncol Dept, Canc Genet Counselling Unit, Elche 03203, Spain

Castillejo A:
 Hosp Gen Univ Elche, Mol Genet Unit, Elche 03203, Spain

Garcia-Diaz J:
 Univ Hosp Principe Asturias, Dept Internal Med, Clin Genet Unit, Alcala De Henares 28805, Spain

Robledo M:
 Spanish Natl Canc Res Ctr CNIO, Hereditary Endocrine Canc Grp, Madrid 28029, Spain

 CIBERER, Madrid 28029, Spain

Teule A:
 Inst Invest Biomed Bellvitge, Catalan Inst Oncol, Hereditary Canc Program, Lhospitalet De Llobregat 08908, Spain

Sanchez R:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Unidad Multidisciplinar Enfermedades Baja Prevale, Alicante 03015, Spain

Zuniga A:
 Hosp Univ Politecn La Fe, Unit Genet, Valencia 46026, Spain

Lastra E:
 Hosp Univ Burgos, Unidad Consejo Genet Canc Hereditario, Serv Oncol Med, Burgos 09006, Spain

Duran M:
 UVA, CSIC, Inst Biol & Genet Mol IBGM, Genet Canc, Valladolid 47003, Spain

Llort G:
 Corp Sanitaria Univ Parc Tauli, Med Oncol Dept, Hereditary Canc Unit, Sabadell 08208, Spain

Yague C:
 Consorci Sanitari Terrassa, Med Oncol Dept, Hereditary Canc Unit, Rubi 08191, Spain

Cajal T:
 Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona 08091, Spain

San Martin C:
 Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona 08091, Spain

Lopez-Fernandez A:
 Hosp Univ Vall dHebron, Med Oncol Dept VHIO, Hereditary Canc Genet Grp, Barcelona 08035, Spain

Balmana J:
 Hosp Univ Vall dHebron, Med Oncol Dept VHIO, Hereditary Canc Genet Grp, Barcelona 08035, Spain

Robles L:
 Hosp Univ 12 Octubre, Unidad Canc Familiar, Serv Oncol Med, Madrid 28041, Spain

Mesa-Latorre J:
 Univ Hosp Principe Asturias, Dept Internal Med, Clin Genet Unit, Alcala De Henares 28805, Spain

Chirivella I:
 Univ Valencia, INCLIVA Biomed Res Inst, Dept Med Oncol, Valencia 46010, Spain

Fonfria M:
 Consorcio Hosp Prov Castellon, Med Oncol Dept, Canc Genet Counselling Unit, Castellon de La Plana 12002, Spain

Ibanez R:
 Hosp Gen Univ Elche, Med Oncol Dept, Canc Genet Counselling Unit, Elche 03203, Spain

Castillejo M:
 Hosp Gen Univ Elche, Mol Genet Unit, Elche 03203, Spain

Escandell I:
 Hosp Gen Univ Elda, Serv Dermatol, Elda 03600, Spain

Gomez L:
 Hosp Univ St Joan de Alicante, Urol Dept, St Joan De Alicante 03550, Spain

Berbel P:
 Univ Miguel Hernandez, Fac Med, Dept Histol & Anat, St Joan De Alicante 03550, Spain

Soto J:
 Hosp Gen Univ Elche, Mol Genet Unit, Elche 03203, Spain
ISSN: 20726694





Cancers
Editorial
Multidisciplinary Digital Publishing Institute (MDPI), ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 12 Número: 11
Páginas:
WOS Id: 000592895600001
ID de PubMed: 33167498

MÉTRICAS